Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracersPET-CTSPECT-CT, and PET-MRI

CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.

CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019. Photo by Dave Fornell.

Feature | Radiation Dose Management | March 04, 2021 | By Dave Fornell
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which...
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-...
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

News | PET Imaging | February 03, 2021
February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry...
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging | January 29, 2021
January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility...
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging

Getty Images

News | PET Imaging | January 18, 2021
January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and...
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep

Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep (cool colors in the left columns), are reactivated when regaining a con-nected state upon emergence from anesthesia (warm colors in the right columns). Graphic courtesy of University of Turku

News | PET Imaging | December 30, 2020
December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal...
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a...
SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

News | Nuclear Imaging | December 18, 2020
December 18, 2020 — SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-...
Researchers at the Beckman Institute for Advanced Science and Technology developed a subspace mass spectrometry imaging approach that accelerates the speed of data acquisition -- without sacrificing the quality -- by designing a model-based reconstruction strategy.

Top, hyperspectral visualization with data from a standard 9-hour experiment compared with hyperspectral visualization with data from a proposed 1-hour experiment. Image courtesy the Beckman Institute for Advanced Science and Technology.

News | SPECT Imaging | December 15, 2020
December 15, 2020 — A new computational mass spectrometry imaging method enables researchers to achieve high mass...
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

News | PET Imaging | December 14, 2020
December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for...

JNM celebrates 60 years of nuclear medicine research. Image courtesy of Society of Nuclear Medicine and Molecular Imaging.

News | Nuclear Imaging | December 14, 2020
December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of...
Post-neoadjuvant therapy changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma

Pre-treatment (A-C) and post-treatment (D-F) images after eight cycles of systemic FOLFIRINOX and consolidative chemoradiation. Baseline CA 19-9 was 145 U/ml. Pre-treatment whole body axial fused PET/MRI showed FDG avid lesion in body of pancreas (arrow, A) with SUVmax 7.1 and SUVgluc 8.0. Lesion was hypo-enhancing on axial contrast-enhanced T1-weighted (T1W) MR image (arrow, B) from focused abdominal PET/MRI and on CT (arrow, C). Pre-treatment CT tumor volume was 10.3 cm3. Post-treatment whole body axial fused PET/MRI showed complete metabolic response (arrow D) with SUVmax 1.9 and SUVgluc 1.9. Lesion was indistinct on axial contrast-enhanced T1W MRI (arrow, E) and CT (arrow, F), and there was upstream pancreatic parenchymal atrophy. Post-treatment CT tumor volume was 0.46 cm3. There was normalization of CA 19-9. Relative change in SUVmax (ΔSUVgluc) was -73%, and relative change in SUVgluc (ΔSUVgluc) was -76%. Based on change in tumor size, response was categorized as partial response per RECIST. Relative change in tumor volume (ΔTvol) was -96%. Pathology showed major pathologic response (College of American Pathologists score 1.) Images courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | PET-MRI | December 10, 2020
December 10, 2020 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR...
Videos | PET-CT | December 04, 2020
This is an example of Canon's Advanced intelligent Clear-IQ Engine (AiCE) AI-driven image reconstruction software that...
Approval provides access to the first and only 64-slice volumetric CT digital SPECT/CT in the market, technology for routine total body 3D imaging in nuclear medicine departments
News | SPECT-CT | December 04, 2020
December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for...
 Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
News | PET Imaging | November 25, 2020
November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their...
ASG well positioned for growth as healthcare marketplace continues to evolve 

Allan Klotsche

News | Radiology Imaging | November 24, 2020
November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named Allan...
Spectrum Dynamics Medical, a leading innovator in diagnostic imaging solutions, announces that its VERITON-CT digital SPECT/CT with personalized scans has received a pediatric program contract from Vizient, Inc., a member-driven healthcare performance improvement company in the U.S.
News | SPECT-CT | November 20, 2020
November 20, 2020 — Spectrum Dynamics Medical, a leading innovator in diagnostic imaging solutions, announces that its...
 MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) program.
News | Prostate Cancer | November 19, 2020
November 19, 2020 — MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in...
Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Feature | Nuclear Imaging | November 12, 2020 | By Willow Ascenzo
Medical imaging procedures such as single-photon emission computed tomography (SPECT) scans, myocardial perfusion scans...